Citations 3
Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study
Link, Brian K. , Day, Bann‐Mo, Zhou, Xiaolei , Dawson, Keith, Cerhan, James R. , Flowers, Christopher R. , Friedberg, Jonathan W. , Cerhan, James R , Link, Brian K , Zelenetz, Andrew D.
British Journal of Haematology | April 3, 2018 | Volume: 184 | Issue: 4 | Pages: 660-663
Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma
Chang, Anne Lynn S. , Lewis, Karl D. , Arron, Sarah T. , Migden, Michael R. , Yoo, Simon , Day, Bann‐Mo, McKenna, Edward , Sekulić, Aleksandar , Solomon, James A.
Oncotarget | October 14, 2016 | Volume: 7 | Issue: 46 | Pages: 76118-76124
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
Nabhan, Chadi , Zhou, Xiaolei , Day, Bann‐Mo, Dawson, Keith, Friedberg, Jonathan W. , Link, Brian K. , Flowers, Christopher R. , Zelenetz, Andrew D. , Cerhan, James R. , Link, Brian K
American Journal of Hematology | April 30, 2016 | Volume: 91 | Issue: 8 | Pages: 770-775
We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004–2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow‐up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72–0.97). Lymphoma‐related mortality (HR, 0.46; 0.23–0.93) and overall survival (HR, 0.63; 0.41–0.97) favored females aged ≤60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770–775, 2016. © 2016 Wiley Periodicals, Inc.